Lyra Therapeutics reports Q3 net loss $6.0M, plans new Phase 3 trial for LYR-210

Lyra Therapeutics, Inc.

2025-Q3 EPS reported -$14.85 revenue$391,000

Cash and cash equivalents $22.1M at Sep 30, 2025; cash runway into Q3 2026.
Net loss for Q3 2025 was $6.0M, down from $11.9M in Q3 2024.
R&D expenses decreased 32% to $4.0M; G&A decreased 43% to $2.2M due to cost reductions.
Planning confirmatory Phase 3 trial of LYR-210 for CRS without nasal polyps following FDA meeting.
Presented positive ENLIGHTEN 2 Phase 3 results at AAO-HNS meeting in October 2025.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-277515
form_type: 8-K
ticker: LYRA
cik: 0001327273
company_name: Lyra Therapeutics, Inc.
filed_at: 2025-11-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.121820+00:00
generated_at: 2026-05-16T20:57:44.049489+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-277515
json_url: https://secwatch.observer/filing/0001193125-25-277515.json
markdown_url: https://secwatch.observer/filing/0001193125-25-277515.md
text_url: https://secwatch.observer/filing/0001193125-25-277515.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1327273/000119312525277515/0001193125-25-277515-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1327273/000119312525277515/lyra-20251112.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-277515

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.